Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19431854 | 0.89 | GSTP1 (0.47) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL13237871 | 0.88 | GSTP1 (0.49) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL19449085 | 0.86 | GSTP1 (0.46) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL10082966 | 0.86 | PDK2 (0.40) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL13881238 | 0.84 | GSTP1 (0.46) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL23758534 | 0.84 | GSTP1 (0.44) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL12964684 | 0.84 | ALB (0.44) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL4403236 | 0.83 | GSTP1 (0.45) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL19769279 | 0.82 | MMP14 (0.43) | GSTP1MEN1MAPTHTTKMT2A | |
| SCHEMBL22434019 | 0.82 | GSTP1 (0.44) | GSTP1MEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825338-B2 | SELECTIVE FUNCTIONALIZATION OF OLIGONUCLEOTIDES WITH CONJUGATE GROUPS WITHOUT THE NEED FOR POST-SYNTHETIC LABELING; SOLID PHASE SYNTHESIS; DEBLOCKING AN ACID LABILE HYDROXYL GROUP AND REACTING WITH A PHOSPHORAMIDITE | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | METTL16, BCDIN3D, GARS1 | GSTP1 1303/4885MEN1 1183/4885MAPT 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.